Quarter Period Consolidated Statement Of Income

Daito Pharmaceutical Co., Ltd. - Filing #7727185

Concept 2017-06-01 to
2018-02-28
2016-06-01 to
2017-02-28
Quarter period consolidated statement of income
Statement of income
Net sales
29,636,902,000 JPY
27,919,155,000 JPY
Cost of sales
23,462,245,000 JPY
22,014,247,000 JPY
Gross profit (loss)
6,174,656,000 JPY
5,904,907,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
2,991,140,000 JPY
2,831,342,000 JPY
Operating profit (loss)
3,185,330,000 JPY
3,075,939,000 JPY
Non-operating income
Interest income
681,000 JPY
647,000 JPY
Dividend income
62,916,000 JPY
63,479,000 JPY
Non-operating income
95,008,000 JPY
93,323,000 JPY
Non-operating expenses
Interest expenses
18,208,000 JPY
21,807,000 JPY
Non-operating expenses
34,951,000 JPY
127,585,000 JPY
Ordinary profit (loss)
3,245,387,000 JPY
3,041,677,000 JPY
Extraordinary income
Extraordinary income
20,524,000 JPY
80,696,000 JPY
Extraordinary losses
Extraordinary losses
525,000 JPY
15,339,000 JPY
Profit (loss) before income taxes
3,265,386,000 JPY
3,107,033,000 JPY
Income taxes
985,177,000 JPY
1,084,709,000 JPY
Profit (loss)
2,280,208,000 JPY
2,022,323,000 JPY
Profit attributable to
Profit (loss) attributable to non-controlling interests
-20,036,000 JPY
-21,337,000 JPY
Profit (loss) attributable to owners of parent
2,300,244,000 JPY
2,043,661,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
156,266,000 JPY
-144,843,000 JPY
Foreign currency translation adjustment
90,938,000 JPY
-52,783,000 JPY
Remeasurements of defined benefit plans, net of tax
3,186,000 JPY
130,982,000 JPY
Other comprehensive income
250,391,000 JPY
-66,644,000 JPY
Comprehensive income
2,530,599,000 JPY
1,955,679,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
2,523,019,000 JPY
1,993,016,000 JPY
Comprehensive income attributable to non-controlling interests
7,580,000 JPY
-37,337,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.